PacBio reported fourth-quarter 2025 revenue of $44.6 million, up 14% year over year and 16% sequentially, with full-year revenue reaching $160 million. Consumables set a quarterly record at $21.6 million, while non-GAAP gross margin improved to 40% in both the quarter and the year. The company narrowed its non-GAAP net loss to $37.6 million in Q4 and to $158.8 million for 2025, while trimming non-GAAP operating expenses to $229.9 million for the year. System placements of the Revio platform slowed to 21 in Q4 and 61 for the year, down from 23 and 97 in 2024, but annualized pull-through per system held around $242,000 in Q4. PacBio exited 2025 with $279.5 million in cash and investments and completed the sale of its short-read assets for approximately $48.1 million. The company is preparing to launch SPRQ-NX in 2026, a platform positioned to materially lower long-read sequencing costs.
The strategic question is whether a tighter, long-read–only focus can convert PacBio’s technical edge into clinical scale before the installed-base momentum stalls. Instrument placements slipped, but utilization is rising and margins are improving, suggesting a maturing user base that is spending more per system. For a tools company seeking to cross from research to clinical, the fulcrum is not just speed or accuracy—it is demonstrable clinical utility at a cost and workflow payers and hospital labs can accept.
This matters now because long-read sequencing is moving from specialist research into areas critical to pharma and health systems: rare disease diagnostics, quality control for cell and gene therapy, and comprehensive structural variant detection that short-read methods struggle to resolve. For patients and HCPs, the promise is fewer diagnostic odysseys and clearer answers in conditions driven by repeat expansions, complex rearrangements, and methylation changes. For payers, the coming cost curve from SPRQ-NX, coupled with growing evidence in networks like iHope, could shift coverage decisions from case-by-case exceptions to defined criteria for first-line testing in select indications. For biopharma teams, long-read data can reshape trial design, patient stratification, and CMC release testing for advanced therapies—areas where regulatory agencies increasingly expect higher-resolution genomics.
The company’s recent moves fit broader industry currents. Platform specialization is accelerating as capital gets redeployed from diffuse portfolios to defensible niches, and as clinical genomics inches toward routine care, the winners will be those who pair technology with evidence generation and access models. Partnerships with iHope, n-Lorem, and EspeRare hint at a hybrid path that blends philanthropic access with real-world evidence creation—an approach that can de-risk payer adoption while seeding future commercial demand. New multiomics capabilities, such as the CiFi method for chromosome-scale assemblies from a single run, point to expanding use cases beyond germline into oncology and epigenetics. Meanwhile, adoption of HiFi as a first-line approach in sudden unexplained death in childhood signals that clinical decision-makers are beginning to assign long-read methods to the front of the diagnostic algorithm, not just as a reflex test.
For Commercial and Medical Affairs leaders, 2026 becomes a proof year. If SPRQ-NX meaningfully bends per-sample costs and PacBio sustains pull-through growth, expect faster lab adoption, stronger payer dialogues anchored in outcomes, and a sharper tilt toward long-read in CGT workflows. If instrument placements remain soft and cost reductions lag, long-read may stay a powerful but niche adjunct. The question for pharma is straightforward: which programs and pipelines will gain a competitive edge by locking in long-read–enabled evidence strategies now, and which will wait until the standard of care has already moved on?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
